The increasing need for new and improved vaccines and the growing level of sophistication of their associated adjuvantation and delivery systems has major implications for the design, formulation, delivery, manufacturing and quality assessment of modern vaccines and immune interventions in general. Following the successful MVAF meetings held in Prague, Dublin and Cannes, the follow-up conference MVAF 2013 will offer an international forum for the discussion of all aspects of vaccine formulation and will focus on:

- Innovation in vaccine design and adjuvantation/delivery technologies
- Challenges to manufacturing and the administration of modern vaccines
- Compliances with quality standards and regulatory requirements

MVAF 2013 will then assess the impact of all of the above on the future development/design of vaccines and adjuvants.

MVAF 2013 will be of interest to researchers/contributors from academic programs, industrial, governmental and regulatory groups. Contributions to both the oral and poster programs are encouraged.

**SCIENTIFIC ADVISORY PANEL**

Conference Chair:
Geert van den Bossche (Smart Vaccine Technologies, Seattle, Washington, USA)

Martin Friede (WHO, Geneva, Switzerland)
Nathalie Garcon (GSK Biologicals, Belgium)
Adriana Baz Morell (CSL Ltd, Melbourne, Australia)
Jean Haensler (Sanofi Pasteur, France)
Danuta Herzyk (Merck Research Laboratories, USA)
Mannohan Singh (Novartis Vaccines, Cambridge, Massachusetts, USA)
Jan-Willem van der Laan (Medicines Evaluation Board, Utrecht, The Netherlands)
Lakshmi Khandke (Pfizer Vaccine Research, Pearl River, New York, USA)
Bruce Weniger (Chiang Mai University, Chiang Mai, Thailand)
Rob Lambkin-Williams (Retroscreen Virology Ltd, London, UK)

Gwyn Davies (St. George’s Hospital, London, UK)
Matthew Downham (Novartis Vaccines & Diagnostics, Siena, Italy)
Greg Glenn (Novavax Inc., Rockville, Maryland, USA)
Alan Shaw (Vendartra Corporation, Cambridge, Massachusetts, USA)
Niranjan Sardeasal (NovoPharmaceuticals, Blue Bell, Pennsylvania, USA)
Gary Ott (Dynavax Inc., San Diego, California, USA)
Heather Davis (Pfizer Vaccines Research, Ottawa, Canada)
Steve Reed (IDRI, Seattle, Washington, USA)
Nicolas Collin (University of Lausanne, Lausanne, Switzerland)
Blaise Genton (CHUV, Lausanne, Switzerland)
Stephane Ascarateal (SEPPIC, Paris, France)
Guro Gafvelin (Viscogel AB, Solna, Sweden)

**CONFERENCE SCOPE/TOPICS**

The following list of topics is not exhaustive but reflects the variety of subjects that this area of vaccine/adjuvant technology and development encompasses:

**Innovative Vaccine Concepts and Designs**
- Molecular Approaches to Vaccine Design
- Vaccine Immunology/Immunogenicity Studies
- Vaccine Design & Formulation
- Modelling Methods
- Vaccine/Adjuvant Delivery Issues & Systems
- Vaccine/Adjuvant Diversity – Live or Inactivated Virus/Recombinant Protein
- Polysaccharide or Peptide (free versus conjugated)
- Viral Vectors/DNA Vectors
- VLPs & Nanoparticulate Vaccines
- Administration Devices/Methods (oral/nasal/transcutaneous/needle-free)

**Process & Manufacturing**
- Protein Stabilization/Virus Stabilization/Vaccine Stabilization
- Vaccine Preservation Issues – New/Novel Vaccine Preservatives
- Vaccine Stability Monitoring Methods

**Characterization and quality assessment in compliance with regulatory guidelines**
- Vaccine/Adjuvant Quality, Purity & Potency/Efficacy & Safety
- Safety Evaluation Considerations
- Assay Development Aspects
- Toxicology Studies
- Regulatory Guidelines – National/International for Adjuvanted Vaccines
Registration

Welcome & Opening Remarks
Geert Van-den Bossche (UNIVAC LLC, Seattle, Washington, USA)

**SESSION 1: OPENING PLENARY**

Moderator: Geert Van-den Bossche (UNIVAC LLC, Seattle, Washington, USA)

- ‘An overview of modern vaccines/adjuvants and their potential future development’
  Ennio de Gregorio (Novartis Vaccines & Diagnostics, Siena, Italy)

- ‘The rationales and trends for future vaccine adjuvants’
  Virgil Schijns (University of Wageningen, Wageningen, The Netherlands)

- ‘Adjuvants: The needs, the knowns, and the known unknowns’
  Martin Friede (WHO, Geneva, Switzerland)

Coffee Break & Poster Set-Up

**SESSION 2: PLENARY II**

Moderator: Martin Friede (WHO, Geneva, Switzerland)

- ‘Addressing the challenge of access to adjuvants’
  Nicolas Collin (University of Lausanne, Epalinges, Switzerland)

- ‘Moving from empiricism and alchemy to rational vaccine design: A badly needed (r)evolution in vaccinology?’
  Geert Van-den Bossche (UNIVAC LLC, Seattle, Washington, USA)

- ‘Adjuvant properties of polyethyleneimine’
  Quentin Sattentau (University of Oxford, Oxford, UK)

Lunch Break & Posters

**SESSION 3: (NANO)PARTICULATE VACCINE ADJUVANTS I**

Moderator: Nicolas Collin (University of Lausanne, Epalinges, Switzerland)

- ‘Nanoparticles as vaccine adjuvants – strategies to enhance immunogenicity’
  Gerrit Borchard (University of Geneva, Geneva, Switzerland)

- ‘Polymeric nanoparticle conjugated antigen and CpG adjuvanted enhance Th1 and cytotoxic CD8+ effector and memory cellular responses’
  Jeffrey A. Hubbell, Marie Ballester, Sachiko Hirose, Chiara Nembrini, Evan A. Scott, Eleonora Simeoni, Armando Stano, Melody A. Swartz and Alexandre de Titta
  (Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland)

- ‘A balanced Th1/Th2/Th17 immune response to a nanoemulsion-inactivated and formulated whole RSV vaccine and its efficacy against live challenge in mouse and cotton rat animal challenge models’
  Ali Fattom (NanoBio Corporation, Ann Arbor, Michigan, USA)

- ‘Matrix –M® – recent clinical and preclinical experience’
  Linda Stertman (Isonova AB, Uppsala, Sweden)

Tea Break & Posters

**SESSION 4: (NANO)PARTICULATE VACCINE ADJUVANTS II**

Moderator: Alan Shaw (Vedantra Corporation, Cambridge, Massachusetts, USA)

- ‘Inter-cilayer cross-linked membrane vesicles, new solutions for old problems in malaria’
  Alan Shaw (Vedantra Corporation, Cambridge, Massachusetts, USA)

- ‘Cationic liposomes as delivery system for a lipooligosaccharide and TbpB based vaccine against group B meningococcal disease’
  F. Dalencon, N. Mistretta, B. Guy, Y. Berard, O. Fratantonio, C. Gregoire, A. Lechellevallier, P. Lheritier, L. Revet, M. Moreau, J. Haensler and B. Rokbi
  (Sanofi Pasteur, Marcy l’Etoile, France)

- ‘Protective antibody and CD8+ T-cell responses to the Plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine’
  David E. Lanar, Stephen A. Kaba, Margaret E. McCoy, Tais A.P.F. Doll, Qin Guo, Debleena Dasgupta and Peter Burkhartd
  (Walter Reed Army Institute of Research, Silver Spring, Maryland, USA)

- ‘Emulsified nanoparticles based on amphiphilic biore sorbable polymers and their role in vaccine immunogenicity’
  Ming-Hsi Huang, Chih-wei Lin, Chung-Yi Huang, Chih-Hsiang Leng, Shih-Jen Liu, Hsin-Wei Chen and Pele Chong
  (National Institute of Infectious Diseases and Vaccinology, Miaoli, Taiwan)

MVAF 2013 Welcome Drinks & Poster Session

**LATE-BREAKER ORAL AND POSTER ABSTRACTS**

The Scientific Advisory Panel have set an extended deadline for Late-Breaker Oral and Poster Abstracts of Friday 22nd March 2013. Prospective authors should submit one page Word or one page PDF documents to the Conference Organizers (Meetings Management) for consideration.

Please send submissions for the attention of John Herriot by e-mail to: jherriot@meetingsmgmt.u-net.com

Late-Breaker Oral and Poster Abstracts should be submitted by Friday 22nd March 2013.
SESSION 5: MODELS FOR ADJUVANT ASSESSMENT

Moderator: Rob Lambkin-Williams (Retroscreen Virology Ltd, London, UK)

‘Novel models to evaluate modern vaccine adjuvants’
Rob Lambkin-Williams (Retroscreen Virology Ltd, London, UK)

‘Employing microphysiology and tissue engineering for age-specific targeting of adjuvanted vaccines’
Ofer Levy (Harvard Medical School, Boston, Massachusetts, USA)

‘New lymphatic targeting strategies for therapeutic vaccination’
Melody A. Swartz, Susan N. Thomas, Laura Jeanbart, Marie Ballester, Alexandre de Titta, Efthymia Vokali and Sachiko Hirose (Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland)

Coffee Break & Posters

SESSION 6: VACCINE ADJUVANT FORMULATION

Moderator: Lakshmi Khandke (Pfizer Vaccine Research, Pearl River, New York, USA)

‘Characterization of vaccine formulations with adjuvants’
Lakshmi Khandke (Pfizer Vaccine Research, Pearl River, New York, USA)

‘Engineering a CD8+ T-cell-inducing vaccine adjuvant through rational formulation design’
Dennis Christensen (Statens Serum Institut, Copenhagen, Denmark)

‘Enhancement of influenza vaccines using novel emulsions’
Ted M. Ross (Vaccine and Gene Therapy Institute of Florida, Port St. Lucie, Florida, USA)

‘Emulsification of recombinant lipoprotein elicits potent immune responses’
Hsin-Wei Chen, Chen-Yi Chiang, Ming-Hsi Huang, Chien-Hsiung Pan, Chun-Hsiang Hsieh, Mei-Yu Chen, Hsueh-Hung Liu, Jy-Ping Tsai, Shih-Jen Liu, Pele Chong and Chih-Hsiang Leng (National Institute of Infectious Diseases and Vaccinology, Miaoli, Taiwan)

Lunch Break & Posters

SESSION 7: VACCINES

Moderator: Heather G. Davis (Pfizer Vaccine Research, Ottawa, Canada)

‘NIC7 anti-nicotine vaccine for smoking cessation’
Heather G. Davis (Pfizer Vaccine Research, Ottawa, Canada)

‘Enteric fever and pneumococcal protein capsular matrix vaccines’
Kevin Killeen (Matrivax Inc., Boston, Massachusetts, USA)

‘Development of the intranasal RSV F subunit vaccine SynGE®’
Kees Leenhouts, Bert Jan Hajlaja, Ivy Widjaja and Alan Rigter (Mucosis BV, Groningen, The Netherlands)

Tea Break & Posters

SESSION 8: LATE-BREAKER & SHORT POSTER PRESENTATIONS

Moderators: To be confirmed

The Scientific Advisory Panel have set an extended deadline for Late-Breaker Oral and Poster Abstracts of Friday 22nd March 2013. Prospective authors should submit one page Word documents to the Conference Organizers (Meetings Management) for consideration.

Please send submissions for the attention of John Herriot by e-mail to: jherriot@meetingsmgmt.u-net.com

Late-Breaker Oral and Poster Abstracts should be submitted by Friday 22nd March 2013.

SESSION 9: OPEN PANEL & INTERACTIVE DISCUSSION

Moderators: To be confirmed
Panel members: To be confirmed

Free Evening For Delegates

LATE-BREAKER ORAL AND POSTER ABSTRACTS

The Scientific Advisory Panel have set an extended deadline for Late-Breaker Oral and Poster Abstracts of Friday 22nd March 2013. Prospective authors should submit one page Word or one page PDF documents to the Conference Organizers (Meetings Management) for consideration.

Please send submissions for the attention of John Herriot by e-mail to: jherriot@meetingsmgmt.u-net.com

Late-Breaker Oral and Poster Abstracts should be submitted by Friday 22nd March 2013.
SESSION 10: ADJUVANT AND VACCINE DELIVERY SYSTEMS

Moderator: Manmohan Singh  
(Novartis Vaccines, Holly Springs, North Carolina, USA)

‘Optimizing delivery of novel immune potentiators’  
Manmohan Singh (Novartis Vaccines, Holly Springs, North Carolina, USA)

‘Delivery systems for peptide vaccines’  
Istvan Toth (The University of Queensland, Brisbane, Queensland, Australia)

‘Self-replicating RNA vaccine delivery to dendritic cells by chitosan-nanogel delivery’  
Panagiota Milona, Isabelle Bassi, Rolf Suter, Nicolas Ruggli and Kenneth C. McCullough  
(Institute of Virology and Immunoprophylaxis, Mittelhausern, Switzerland)

‘Induction of potent CD8+ T cell responses through the delivery of vaccines to skin antigen-presenting cells (APCs) using a microprotection array (Nanopatch™)’  
Germain J.P. Fernando, Hwee-Ing Ng and Mark A.F. Kendall  
(The University of Queensland, Brisbane, Queensland, Australia)

SESSION 11: TLRS AND CLRS

Moderator: To be confirmed

‘In vitro evaluation of TLR4 agonist activity: Formulation effects’  
Christopher Fox (IDRI, Seattle, Washington, USA)

‘A Polyvalent Toll-like receptor 9 nanoparticle ligand as adjuvant for a prophylactic vaccine against B. anthracis (Antrax)’  
Gary Ott, Holger Kanzerl, C Calacaen, M. Kachura, S.K. Kell, G. Ott, R. Kiwan, R. Milley, R. L. Coffman (Dynavax, Berkeley, California, USA)

‘Ligands for toll-like and C-type lectin receptors for targeting and activating dendritic cells’  
Kenneth C. McCullough, Rani Sharma, Brigitte Herrmann, Evgeniya Rapoport, Nicolai Bovin, Isabelle Bassi, Panagiota Milona, Thomas Demoulins and Arin Ghasparian  
(Institute of Virology and Immunoprophylaxis, Mittelhausern, Switzerland)

Lunch Break & Posters

SESSION 12: ADJUVANTS

Moderator: Ali Harandi  
(University of Gothenburg, Gothenburg, Sweden)

‘Biomarkers of experimental mucosal adjuvants’  
Ali Harandi (University of Gothenburg, Gothenburg, Sweden)

‘Complement as natural adjuvant’  
Martin Bachmann (University of Zurich, Zurich, Switzerland)

‘A novel combination adjuvant for mucosal vaccination against respiratory syncytial virus’  
(VIDO-Intervet, University of Saskatchewan, Saskatoon, S7N 5E3, Canada)

‘Clinical results from a phase I/II trial with the chitosan based adjuvant Viscogel’  
Guro Gafvelin (Viscogel AB, Solna, Sweden)

‘Novel vaccine adjuvant for induction of cellular and humoral immunity’  
Vincent Serra (Wittcell SA, Rheims, France)

Tea Break & Poster Breakdown

SESSION 13: ADJUVANTS FOR THERAPEUTIC VACCINES

Moderator: Adriana Baz Morelli  
(CSL Limited, Parkville, Victoria, Australia)

‘Enhancing the efficacy of cancer therapeutic monoclonal antibodies with ISCOMAB formulation: a technology based upon ISCOMATRIX adjuvant’  
Adriana Baz Morelli (CSL Limited, Parkville, Victoria, Australia)

‘Delayed type hypersensitivity reactions correlating with overall survival in patients with metastatic melanoma, after vaccination with peptides, Cpg and Montanide’  
Daniel E. Speiser (University of Lausanne, Lausanne, Switzerland)

‘Montanide ISA 51 VG and Montanide ISA 720 VG, adjuvants dedicated to therapeutic vaccines’  
Stephane Ascaratelli (SEPPIC, Paris, France)

‘Targeting the tumor-draining lymph node with a nanoparticle vaccine enhances its therapeutic efficacy as cancer immunotherapy’  
Laura Jeanbart, Patricia Corthsy, Marie Ballester, Alexandre de Titta, André van der Vlies, Jeffrey A. Hubbell and Melody A. Swartz  
(Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland)

Coffee Break & Posters

SESSION 14: CLOSING PLENARY PRESENTATIONS

Moderator: Geert Van-den Bossche  
(UNIVAC llc., Seattle, Washington, USA)

‘Vaccine CMC – anticipating the regulator’  
Brijesh Patel (MHRA, London, UK)

‘Safety of adjuvanted vaccines: focus on autoimmunity, report from a HESI-workshop’  
Jan Willem van der Laan  
(Medicines Evaluation Board, Utrecht, The Netherlands)

Closing Remarks & Departure

POSTERS

‘Alginate-coated chitosan nanogel capacity to modulate the effect of TLR ligands on blood dendritic cells’  
Thomas Demoulins, Isabelle Bassi and Kenneth C. McCullough  
(Institute of Virology and Immunoprophylaxis, Mittelhausern, Switzerland)

‘Recombinant liopoimmunogen based intrinsic adjuvant for vaccine design and adjuvantation’  
Chi-hsiang Leng, Shih-Jen Liu, Hsueh-Yung Liu, Yan Kwok, Chang-Ling Lin, Li-Hsiu Lin, Mei-Yu Chen, Jy-Ping Tsai, Li-Sheng Chang, Fang-Feng Chiu, Li-Wei Lai, Wei-Cheng Lian, Chiou-Ying Yang, Shih-Yang Hsieh, Ching-Yi Huang, Jeremy J.W. Chen and Pele Chong  
(National Institute of Infectious Diseases and Vaccinology, Miaoli, Taiwan)

‘Induction of potent CD8+ T cell responses through the delivery of vaccines to skin antigen-presenting cells (APCs) using a microprotection array (Nanopatch™)’  
Germain J.P. Fernando, Hwee-Ing Ng and Mark A.F. Kendall  
(The University of Queensland, Brisbane, Queensland, Australia)

* This provisional programme is correct at the time of printing. However the organisers reserve the right to make any alterations that may be required in the interests and integrity of the final conference programme. A final programme with timings will be available in April 2013.
REGISTRATION

Delegates should register for MVAF 2013 by completing the form provided on the back page of this brochure. The completed Conference Registration Form plus payment (payment in £ Pounds Sterling) should be sent to the MVAF 2013 Conference Manager – Caroline Sumner at Meetings Management. The MVAF 2013 Conference Registration Desk will be open from 8.00am on Wednesday 15th May 2013.

Delegates can also register securely on-line at:
www.meetingsmanagement.com/mvaf_2013

VENUE & ACCOMMODATION

MVAF 2013 will be held at: CHUV, Lausanne, Switzerland.

Accommodation: there are numerous hotels in Lausanne to suit most budgets. For information details on accommodation in Lausanne and other useful information, please visit:

Please note that the MVAF 2013 conference organizers will not be recommending any specific hotels in Lausanne.

May is a busy time in Lausanne and it is recommended that MVAF 2013 delegates book their accommodation without delay.

PUBLICACIÓN

A CD ROM of final programme and abstracts of all presentations, oral and poster, will be distributed to delegates when they register at the conference.

TABLE TOP EXHIBITION

Table Top Exhibition space is available at the meeting. Exhibitors can showcase their products or services by reserving a table top exhibit. The exhibit area will be located where all refreshments breaks will be taken to ensure maximum traffic of conference delegates. If you are registering for the conference, you can reserve a table for £1200. If you do not wish to attend the conference sessions, you can reserve a table for £2500 (includes admission to all meals/receptions by one company representative).

PLEASE NOTE: If you wish to have additional representatives on your table top exhibit there will be an additional charge for catering levied per head. Please contact the Conference Manager for this additional price.

For more information contact John Herriot at Meetings Management (E-mail: jherriot@meetingsmgmt.u-net.com).

IDEA CANNOT ATTEND?

If you and your colleagues are unable to attend the conference, the conference materials (abstract booklet, speaker handouts, late abstracts, attendee list, pack materials and literature) are available for purchase. While not intended as a substitute for actual attendance, these materials would at least provide a documentary record of the event and allow you to keep you or your organization's library up to date. The cost of providing this non-attendee package is £425 (including postage and packing). To order this package from Meetings Management please use the relevant section in the Delegates Registration Form on the back page of this brochure.

ANY QUESTIONS?

For further information and assistance, please contact: Caroline Sumner MVAF 2013 Conference Manager:

MVAF 2013 Conference Secretariat, Meetings Management
The Old Dairy Tower, Peper Harow Park, Godalming
Surrey, GU8 6BD, United Kingdom.

Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516
E-mail: csumner@meetingsmgmt.u-net.com

LATE-BREAKER ORAL AND POSTER ABSTRACTS

The Scientific Advisory Panel have set an extended deadline for Late-Breaker Oral and Poster Abstracts of Friday 22nd March 2013. Prospective authors should submit one page Word or one page PDF documents to the Conference Organizers (Meetings Management) for consideration.

Please send submissions for the attention of John Herriot by e-mail to: jherriot@meetingsmgmt.u-net.com

Late-Breaker Oral and Poster Abstracts should be submitted by Friday 22nd March 2013.
Please tick appropriate boxes and write clearly in BLOCK CAPITALS or type.

Surname ............................................ Initials ............................................ Title ............................................
Organization ............................................ Address ............................................

Country ............................................ Telephone ............................................ Postcode ............................................
E-mail (plain type or print): ............................................

If you are an EC business please state your VAT registration number: ............................................

Disabled (please state any special needs): ............................................ Special diet (please state requirements): ............................................

---

**REGISTRATION FEES**

**Speaker/Delegate Registration Fees:**

- [ ] Speaker Registration (submitted oral/poster papers) (£630.00)
- [ ] Reduced Early Bird Registration (£730.00)
- [ ] Full Registration (£975.00)

**Table Top Exhibits/Delegate Pack Inserts**

- [ ] Table Top Exhibit (I am registered to attend) (£1200.00)
- [ ] Delegate Pack Insert (£455.00)

**For those Unable to Attend**

- [ ] Set(s) of MVAF 2013 materials (£425.00 (per set))

**Total Amount Payable**

Registration fees include admission to all conference sessions, morning and afternoon refreshments, lunches on the 15th, 16th and 17th of May 2013 and the Welcome Reception drinks.

---

**PAYMENT**

- [ ] I enclose a cheque for £ ............................................ made payable to Meetings Management. (Delegates registering from outside the UK must ensure that cheques are drawn on a London Bank. Please quote MVAF 2013 on the reverse of the cheque.)

- [ ] I have made a payment by bank transfer (quoting MVAF 2013 on the transfer documentation) to Barclays Bank, Barclays Business Centre, Guildford Branch, PO Box 33, Guildford, Surrey GU1 3AN, UK:
  - UK Pounds Sterling Account: Meetings Management 0040614335,
  - IBAN GB02BARC20353540614335 SWIFTBIC BARCGB22
  - Euro Account: Meetings Management 59179600,
  - IBAN GB02BARC2035359179600 SWIFTBIC BARCGB22

All transfer charges must be paid by the sender. Delegates paying by this method are requested to send the Conference Manager a copy of the bank transfer.

**Payments made by bank transfer must have £15.00 added to the total. PINGEL NOTE THAT IT WILL NOT BE POSSIBLE TO PAY REGISTRATION FEES BY BANK TRANSFER AFTER FRIDAY 12TH APRIL 2013. LATE PAYMENT AFTER FRIDAY 12TH APRIL 2013 MUST BE MADE BY CREDIT CARD (VISA/MASTERCARD/AMEX).**

- [ ] I would like to pay £ ............................................ by credit card (VISA/MasterCard/AMEX only accepted).
  - Card no. ............................................
  - 3 Digit Security Code (AMEX: 4 Digits) ............................................
  - Expiry Date ............................................
  - Registered Card Address ............................................

---

Please remember that any remittance sent but not received by the time of the conference must be paid again at the Registration desk: we will refund you after the conference. Cancellations received before Friday 12th April 2013 will be refunded in full less an administrative charge of £150 per person. Refunds will not be possible if a cancellation is received after Friday 12th April 2013. Substitutions can be made at any time prior to the conference. Please inform the Conference Manager of any changes. We strongly advise that delegates purchase travel insurance to cover any unforeseen circumstances and protect against loss of hotel deposits and registration fees.

---

**PLEASE RETURN THIS FORM TO:**

MVAF 2013 CONFERENCE SECRETARIAT, MEETINGS MANAGEMENT

Unit 6, Hurtmore Heights Commercial Centre, Hurtmore Road, Hurtmore, Godalming, Surrey GU7 2FD, United Kingdom

Conference Manager: Caroline Sumner Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516 E-mail: csumner@meetingsmgmt.u-net.com

---

Secure on-line registration is now open at: www.meetingsmanagement.com/mvaf_2013